Our Team

Dr Moore’s four decade career has focused on the regulation of cell production in the body’s two most regenerative tissues: the bone marrow and the single layer of the intestinal mucosa.

His PhD research conducted at the US National Institutes of Health (NIH) changed the origin of the genetic basis of paroxysmal nocturnal haemaglobinuria (PNH).

Dr Moore’s search for regulators of cell production started as a post-doctoral fellow of Prof Don Metcalf at the Walter and Elisa Hall Institute (WEHI) in Melbourne, the founder of the field of blood cell production.

Based on some early research, Dr Moore set out at WEHI to identify the body’s regulators that protect stem cells (engine for cell production) from the toxicity of chemotherapy. The search continued at DNAX Research Institute in Palo Alto and at ImClone Systems Inc in New York City.

At ImClone, Dr Moore discovered a protein (FRIL) that maintained blood stem cells in culture for extended periods and were capable of repopulating long-term blood cell production. He founded Phylogix Inc in the Boston area and advanced FRIL to late preclinical development with $15m venture capital funding from Atlas Venture, Biotechnology Value Fund, Canaan Partners, Prospect Venture Partners and Radius Ventures.

Dr Moore then moved to the body’s other most regenerative tissue, the mucosal layer of the gut. He joined Prof Chris Potten, founder of the epithelial stem cell field, at Epistem Ltd in Manchester, UK. Dr Moore created and led a regenerative medicine collaboration with Novartis Institutes of BioMedical Research (NIBR), where his team developed and validated in vitro models that delivered the core technology at Curileum.

Jeff received a PhD from George Washington University in Genetics from Washington University after obtaining a BA in Chemistry from Colorado College.

Mohini leads the in vitro characterisation of ULI262 at Curileum.

She is the Lead Scientist with a broad expertise in cell biology. Before joining Curileum, she led complex bioanalytical projects at Synexa Life Sciences and contributed to the COVAC1 self-amplifying RNA vaccine trial at Imperial College London. Her work spans clinical trials in infectious disease and oncology, with publications in The Lancet, Journal of Clinical Investigation, and Cell Reports.

Mohini received a  MSc in Immunology (Distinction) from Imperial College London and a BA (Hons) in Biological Natural Sciences from the University of Cambridge.

Nate has lead the identification and the continued extensive physicochemical characterisation of ULI262.

He is an Emeritus Professor of Chemistry at Colorado College, where he spent four decades applying analytical chemistry to challenges spanning forensic science, environmental ecology, and analytical characterisation of rare materials.

Nate received a PhD from Oregon State University after receiving a BA from the College of Wooster.

Darren Dixon is Professor of Chemistry at the University of Oxford and a leading contributor in synthetic methodology. As CSO and Founder of Cortex Organics, he pioneers novel synthetic routes to complex molecules. His work bridges academic discovery with commercial application in drug development.

Yao Shi leads the synthesis of ULI262 at Curileum.

He is chemist and entrepreneur, serving as CEO and Founder of Cortex Organics. With a PhD in synthetic chemistry, he has developed innovative strategies for scalable synthesis of complex molecules. Yao leads Cortex in supporting pharma and biotech partners with bespoke chemistry solutions.

Yao received a PhD from the University of Oxford after obtaining MSc and BSc degrees from the Cambridge University in Organic Chemistry.

Sir John Burn is Professor of Clinical Genetics at Newcastle University and a Fellow of the Academy of Medical Sciences. A global authority in hereditary cancer syndromes, he has pioneered research and clinical practice in genomics, cancer prevention, and precision medicine.

Mark Hull is Professor of Molecular Gastroenterology at the University of Leeds and Co-Founder of COLO-PREVENT. His research emphasizes colorectal cancer prevention, inflammation-associated carcinogenesis, and translational clinical trials designed to test preventive interventions.